| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
CLINICAL STUDY |
Departments of Medical Sciences, 1 Ophthalmology, 2 Radiology 3 Otolaryngology and 4 Internal Medicine, University of Milan, Fondazione Ospedale Maggiore IRCCS, Milan, Italy, 5 Pathology Unit, Department of Medicine, Surgery and Dentistry, Ospedale San Paolo, Milan and 6 Division of Internal Medicine, Ospedale di Fidenza, Parma, Italy
(Correspondence should be addressed to P Beck-Peccoz; Email: paolo.beckpeccoz{at}unimi.it)
Introduction: Hyperthyroid Graves’ disease (GD) is a B-cell-mediated condition caused by TSH receptor antibodies (TRAb), which decline when GD remits. Anti-CD20 monoclonal antibody rituximab (RTX) induces transient B-cell depletion that may potentially modify the active inflammatory phase of thyroid-associated ophthalmopathy (TAO).
Methods: Nine patients with GD, (seven with active TAO, two with mild lid signs) were studied. The trial was only approved as an open pilot study; thus we compared the effect of RTX therapy to that of i.v. glucocorticoids (IVGC) in 20 consecutive patients. Patients were treated with RTX (1000 mg i.v. twice at 2-week interval) or with IVGC (500 mg i.v. for 16 weeks). TAO was assessed by the clinical activity score (CAS) and severity was classified using NOSPECS (No signs or symptoms; Only signs (lid); Soft tissue involvement; Proptosis, Extraocular muscle involvement; Corneal involvement; Sight loss). Thyroid function and lymphocyte count were measured by standardized methods.
Results: All patients attained peripheral B-cell depletion with the first RTX infusion. Minor side effects were reported in three patients. Thyroid function was not affected by RTX therapy and hyperthyroid patients required therapy with methimazole. After RTX, the changes in the levels of thyroglobulin antibodies, thyroperoxidase antibodies and TRAb were neither significant nor correlated with CD20+ depletion (P = NS). CAS values before RTX were 4.7 ± 0.5 and decreased to 1.8 ± 0.8 at the end of follow-up (P < 0.0001) and more significantly compared with IVGC (P < 0.05). Proptosis decreased significantly after RTX both in patients with active TAO (ANOVA; P < 0.0001) and those with lid signs (ANOVA; P < 0.003). The degree of inflammation (class 2) decreased significantly in response to RTX (ANOVA; P < 0.001). Relapse of active TAO was not observed in patients treated with RTX, but occurred in 10% of those treated with IVGC, who also experienced adverse effects more frequently (45 vs 33% of patients).
Conclusions: RTX positively affects the clinical course of TAO, independently of either thyroid function or circulating antithyroid antibodies, including TRAb. If our findings are confirmed in large controlled studies, RTX may represent a useful therapeutic tool in patients with active TAO.
This article has been cited by other articles:
|
|
 |
|
  R. S. Douglas, A. Tsirbas, M. Gordon, D. Lee, N. Khadavi, H. C. Garneau, R. A. Goldberg, K. Cahill, P. J. Dolman, V. Elner, et al. Development of Criteria for Evaluating Clinical Response in Thyroid Eye Disease Using a Modified Delphi Technique Arch Ophthalmol, September 1, 2009; 127(9): 1155 - 1160. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. V. Misharin, Y. Nagayama, H. A. Aliesky, Y. Mizutori, B. Rapoport, and S. M. McLachlan Attenuation of Induced Hyperthyroidism in Mice by Pretreatment with Thyrotropin Receptor Protein: Deviation of Thyroid-Stimulating to Nonfunctional Antibodies Endocrinology, August 1, 2009; 150(8): 3944 - 3952. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Bartalena and M. L. Tanda Graves' Ophthalmopathy N. Engl. J. Med., March 5, 2009; 360(10): 994 - 1001. [Full Text] [PDF]
|
|
|
|
 |
|
 K. A Heemstra, R. E Toes, J. Sepers, A. M Pereira, E. P Corssmit, T. W J Huizinga, J. A Romijn, and J. W Smit Rituximab in relapsing Graves' disease, a phase II study Eur. J. Endocrinol., November 1, 2008; 159(5): 609 - 615. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Rodien Rituximab in Graves' disease Eur. J. Endocrinol., November 1, 2008; 159(5): 515 - 516. [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Anderson Update in Endocrine Autoimmunity J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 3663 - 3670. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Yu, R. Dunn, M. R. Kehry, and H. Braley-Mullen B Cell Depletion Inhibits Spontaneous Autoimmune Thyroiditis in NOD.H-2h4 Mice J. Immunol., June 1, 2008; 180(11): 7706 - 7713. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Bartalena, L. Baldeschi, A. Dickinson, A. Eckstein, P. Kendall-Taylor, C. Marcocci, M. Mourits, P. Perros, K. Boboridis, A. Boschi, et al. Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO Eur. J. Endocrinol., March 1, 2008; 158(3): 273 - 285. [Full Text] [PDF]
|
|
|
|
|
|
T. J. Smith B Cell Depletion in Graves' Disease: The Right Answer to the Wrong Question? J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1620 - 1622. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
